Trial Profile
A phase I comparative crossover PK study of controlled-release (CR) anagrelide [GALE 401] vs. IR reference product in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jun 2016
Price :
$35
*
At a glance
- Drugs Anagrelide (Primary)
- Indications Essential thrombocythaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 13 Jun 2016 Combined safety data from five phase I trials and a phase II trial published in a Galena Biopharma media release.
- 19 May 2016 Combined safety data from five phase I trials and a phase II trial will be presented at the European Hematology Association 21st Congress, according to a Galena Biopharma media release.
- 30 Dec 2014 New trial record